Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

X4 Pharmaceuticals, Inc

CIK 1501697 XFOR·Biological Products · All EDGAR filings ↗

Going concern Filing comparison

X4 Pharmaceuticals, Inc disclosed substantial doubt about its ability to continue as a going concern

No going-concern disclosure Substantial doubt about ability to continue as a going concern

All intercompany accounts and transactions have been eliminated. Liquidity The Company has evaluated whether there are certain conditions and events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the consolidated financial statements are issued. Although the Company has an approved drug product, licensing and sales of its drug product over the next 12 months will not be sufficient to fund its operating expenses. Since inception, the Company has incurred significant operating losses and…
Evidence
Blank check
No
Comparable
Yes
Current state
substantial_doubt
Current state label
Substantial doubt about ability to continue as a going concern
Direction
escalated
Located in
filing body
Prior filed
2025-03-26
Prior form
10-K
Prior state
none
Prior state label
No going-concern disclosure
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.